Cancer Therapy Advisor: “Is Drugmaker Funding for Patient Groups a Hidden Culprit in Rising Drug Prices?”

November 30, 2016

Bryant Furlow

Drugmakers contribute $50 million each year to the Leukemia and Lymphoma Society, more than a sixth of the group’s overall funding. Colon Cancer Alliance receives more than half of its funding—more than $1 million a year—from industry.1

PhRMA, the pharmaceutical industry’s lobby, asserts that drugmakers have a “natural alliance” with patient advocacy groups. But several experts who spoke with Cancer Therapy Advisor were blunt in their assessments of potential problems inherent to industry funding for patient groups.